Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 1.00 |
| ▸ | HTR2B | P41595 | 13/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.67 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.67 |
| ▸ | HTR3A | P46098 | 1/20 | 0.67 |
| ▸ | HTR6 | P50406 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622371 | 0.84 | HTR2C (1.00) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| SCHEMBL1622306 | 0.84 | HTR2C (1.00) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| SCHEMBL1622246 | 0.84 | HTR2C (0.72) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| SCHEMBL1620274 | 0.81 | HTR2C (1.00) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL1622319 | 0.80 | HTR2C (0.97) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| SCHEMBL1623428 | 0.78 | HTR2C (1.00) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| SCHEMBL1621843 | 0.77 | HTR2C (1.00) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| SCHEMBL18550078 | 0.76 | HTR2C (0.62) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| SCHEMBL1622667 | 0.75 | HTR2C (0.79) | HTR2CHTR2BHTR2ACHRM4CHRM5 | |
| SCHEMBL1624015 | 0.75 | HTR2C (1.00) | HTR2CHTR2BHTR2ACHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| EP-2139896-A1 | PYRIMIDO [4, 5-D]AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | Pfizer Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008117169-A1 | PYRIMIDO [4, 5-D] AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | PFIZER LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008117169-A1 | PYRIMIDO [4, 5-D] AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | PFIZER LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 4/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.